Date: Sept. 23, 2022

Source: JNU's Institute of Medical Microbiology

Translator: ZHANG Xiaoting

Microbiology and two other JNU disciplines ranked among the top 1% in Essential Science Indicators (ESI) subjects in the world for the first time, according to the latest statistics released by Clarivate Analysis on Sept. 8. To date, JNU has had 17 disciplines among ESI's top 1%, ranking second among universities in Guangdong and 61st among Chinese mainland universities – another important achievement in JNU's construction as a double first-class university and high-level university.

(JNU's microbiology discipline ranking）

JNU's microbiology discipline was jointly established by the Institute of Medical Microbiology, the College of Life Science and Technology and the School of Medicine. Attaching great importance to its development, JNU founded the institute in 2017 by introducing well-known scholars in microbiology/virology from China and abroad. Five years later, as the institute gradually evolves as a constant innovator in microbiological research, the discipline has shown remarkable all-around growth.

In those five years, the institute has published over 100 high-level academic papers and obtained 19 national invention patents out of 30 applications. It was approved to build the Guangdong Provincial Key Laboratory of Virology in 2019. To fulfill the obligation to disseminate scientific knowledge and promote the scientific spirit, the microbiology team has held many national academic conferences on virology to popularize related knowledge in society.

The team prioritizes collaborative government-industry-university-research innovation, especially the commercialization and industrialization of research findings, as demonstrated by its cooperation with local governments and enterprises to establish the Biomedical Industry Park of JNU, the Institute of Medical Microbiology in Foshan and the JNU-BIOKANGTAI Vaccine Industrial Institute. The team members contribute to technological advancement and economic growth with significant progress in the research and development or industrialization of regenerative medicine, anti-epidemic substances, medical devices, traditional Chinese medicine products, cell preparation, cell storage, oncolytic virus, chimeric antigen receptor T-cell immunotherapy, new vaccines, and new antiviral and anti-aging drugs.